Cedars-Sinai’s Ravi Thadhani, MD, MPH, Elected to National Academy of Medicine
Executive Vice President of Clinical Affairs and Chief Medical Officer Honored for Academic Leadership, Pioneering Contributions in Nephrology and Preeclampsia
Ravi Thadhani, MD, MPH, executive vice president of Clinical Affairs and chief medical officer for Cedars-Sinai Medical Center and Cedars-Sinai Health System, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
An internationally respected leader in clinical and translational research, Thadhani is known for his groundbreaking work in nephrology and preeclampsia, a leading cause of maternal and perinatal morbidity and mortality. Thadhani recently rejoined Cedars-Sinai after serving as vice dean for Research and Education at Cedars-Sinai Medical Center from 2017 to 2019.
“We congratulate Dr. Thadhani on this well-earned recognition by the National Academy of Medicine,” said Peter L. Slavin, MD, president and CEO of Cedars-Sinai Medical Center and Cedars-Sinai Health System. “This prestigious honor is a testament to Dr. Thadhani’s enduring commitment to academic medicine, research, and patient care, and the transformative impact of his work in nephrology and maternal health.”
Thadhani is the fourth Cedars-Sinai physician elected to the academy. He joins Ophir Klein, MD, PhD, executive director of Cedars-Sinai Guerin Children’s and executive vice dean of Children’s Health; David Rowitch, MD, PhD, deputy director for Research at Guerin Children’s; and Slavin.
In its announcement, the academy cited Thadhani “for visionary leadership at three academic health centers and for pioneering research leading to the first FDA-approved test to predict preeclampsia.”
Thadhani served previously as executive vice president for Health Affairs at Emory University. Prior to Emory, he was a professor of Medicine at Harvard Medical School and chief academic officer and dean for Faculty Affairs at Mass General Brigham.
As vice dean for Research and Education at Cedars-Sinai, Thadhani worked with colleagues to produce groundbreaking research predicting which pregnant women are at risk for a severe form of preeclampsia. The Cedars-Sinai team—with the support of Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty—also developed the nation’s first-ever preeclampsia diagnostic test approved by the FDA.
Thadhani has rejoined the team involved in this research: Anders Berg, MD, PhD, vice chair of Clinical Pathology; S. Ananth Karumanchi, MD, professor of Medicine and director of the Renovascular Research Center; and Sarah J. Kilpatrick, MD, PhD, chair of the Department of Obstetrics and Gynecology.
“Election to the National Academy of Medicine is a tremendous honor and a highlight of my career,” Thadhani said. “This recognition also extends to my dedicated colleagues, who share a commitment to advancing research that improves lives. I am deeply grateful.”
Read more on the Cedars-Sinai Blog: How To Navigate a High-Risk Pregnancy